U.S. patent application number 16/940504 was filed with the patent office on 2020-11-12 for 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds.
The applicant listed for this patent is Eli Lilly and Company. Invention is credited to Nicolas Jacques Francois Dreyfus, Jose Eduardo Lopez, Leonard Larry Winneroski, JR., Eric Michael Woerly.
Application Number | 20200354370 16/940504 |
Document ID | / |
Family ID | 1000004978320 |
Filed Date | 2020-11-12 |
View All Diagrams
United States Patent
Application |
20200354370 |
Kind Code |
A1 |
Dreyfus; Nicolas Jacques Francois ;
et al. |
November 12, 2020 |
6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds
Abstract
The present invention provides a compound of Formula I:
##STR00001## wherein R is hydrogen or methyl; and Z is:
##STR00002## or a pharmaceutically acceptable salt thereof, and the
use of compounds of Formula I for treating neurodegenerative
diseases, such as Alzheimer's disease.
Inventors: |
Dreyfus; Nicolas Jacques
Francois; (Waybridge, GB) ; Lopez; Jose Eduardo;
(Fishers, IN) ; Winneroski, JR.; Leonard Larry;
(Greenwood, IN) ; Woerly; Eric Michael;
(Indianapolis, IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Eli Lilly and Company |
Indianapolis |
IN |
US |
|
|
Family ID: |
1000004978320 |
Appl. No.: |
16/940504 |
Filed: |
July 28, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16576080 |
Sep 19, 2019 |
10752632 |
|
|
16940504 |
|
|
|
|
62736588 |
Sep 26, 2018 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 471/04 20130101;
C07D 487/04 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; C07D 471/04 20060101 C07D471/04 |
Claims
1. A compound of the formula: ##STR00043## wherein R is hydrogen or
methyl; and Z is: ##STR00044## or a pharmaceutically acceptable
salt thereof.
2. The compound according to claim 1 wherein the methyl at position
5 on the pyrrolidine ring is in the cis configuration relative to
the oxygen at position 3: ##STR00045## or a pharmaceutically
acceptable salt thereof.
3. The compound according to claim 2 wherein R is methyl; or a
pharmaceutically acceptable salt thereof.
4. The compound according to claim 2 wherein R is hydrogen; or a
pharmaceutically acceptable salt thereof.
5. The compound according to claim 3 wherein R is methyl in the
(S)-configuration; or a pharmaceutically acceptable salt
thereof.
6. The compound according to claim 3 wherein R is methyl in the
(R)-configuration; or a pharmaceutically acceptable salt
thereof.
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. The compound according to claim 1 wherein the compound is:
##STR00046## or a pharmaceutically acceptable salt thereof.
12. (canceled)
13. (canceled)
14. (canceled)
15. The compound according to claim 1 wherein the compound is:
##STR00047## or a pharmaceutically acceptable salt thereof.
16. (canceled)
17. A method of treating Alzheimer's disease in a patient,
comprising administering to a patient in need of such treatment an
effective amount of a compound of claim 1, or a pharmaceutically
acceptable salt thereof.
18. A method of preventing the progression of mild cognitive
impairment to Alzheimer's disease in a patient, comprising
administering to a patient in need of such treatment an effective
amount of a compound of claim 1, or a pharmaceutically acceptable
salt thereof.
19. A method of treating progressive supranuclear palsy in a
patient, comprising administering to a patient in need of such
treatment an effective amount of a compound of claim 1, or a
pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition, comprising a compound or a
pharmaceutically acceptable salt thereof according to claim 1 with
one or more pharmaceutically acceptable carriers, diluents, or
excipients.
Description
[0001] The present invention relates to novel
6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds, to pharmaceutical
compositions comprising the compounds, to methods of using the
compounds to treat neurodegenerative disorders such as Alzheimer's
disease (AD), and to intermediates and processes useful in the
synthesis of the compounds.
[0002] The present invention is in the field of treatment of AD,
progressive supranuclear palsy (PSP), and other diseases and
disorders involving tau-mediated neurodegeneration, known
collectively as tauopathies.
[0003] AD is a devastating neurodegenerative disorder that affects
millions of patients worldwide. In view of the currently approved
agents on the market which afford only transient symptomatic
benefits to the patient, there is a significant unmet need in the
treatment of AD.
[0004] The oligomerization of the microtubule-associated protein
tau into filamentous structures such as paired helical filaments
(PHFs) and straight or twisted filaments, which give rise to
neurofibrillary tangles (NFTs) and neuropil threads (NTs), is one
of the defining pathological features of AD and other tauopathies.
The number of NFTs in the brains of individuals with AD has been
found to correlate closely with the severity of the disease,
suggesting tau has a key role in neuronal dysfunction and
neurodegeneration (Nelson et al., J Neuropathol Exp Neurol., 71(5),
362-381 (2012)). Tau pathology has been shown to correlate with
disease duration in PSP in that cases with a more aggressive
disease course have a higher tau burden than cases with a slower
progression. (Williams et al., Brain, 130, 1566-76 (2007)).
[0005] Past studies (Yuzwa et al., Nat Chem Biol, 4(8), 483-490
(2008)) support the therapeutic potential of O-GNAcase (OGA)
inhibitors to limit tau hyperphosphorylation, and aggregation into
pathological tau, for the treatment of AD and related tau-mediated
neurodegeneration disorders. More recently, the OGA inhibitor
Thiamet-G has been linked to slowing motor neuron loss in the JNPL3
tau mouse model (Yuzwa et al., Nat Chem Biol, 8, 393-399 (2012)),
and to a reduction in tau pathology and dystrophic neurites in the
Tg4510 tau mouse model (Graham et al., Neuropharmacology, 79,
307-313 (2014)). Accordingly, OGA inhibitors are recognized as a
viable therapeutic approach to reduce the accumulation of
hyperphosphorylated, pathological forms of tau.
[0006] US 2017/0298082 discloses certain glycosidase inhibitors
useful in treating tauopathies such as AD. WO 2018/109198 A1 and WO
2018/109202 A1 disclose certain OGA inhibitors useful for treating
tauopathies, such as AD and PSP.
[0007] OGA inhibitors that are brain penetrant are desired to
provide treatments for tau-mediated neurodegeneration disorders,
such as AD and PSP. The present invention provides certain novel
compounds that are potent inhibitors of OGA. In addition, the
present invention provides certain novel compounds that are potent
inhibitors of OGA with the potential to be sufficiently brain
penetrant to effectively treat tauopathies, such as AD and PSP.
[0008] Accordingly, the present invention provides a compound of
Formula I:
##STR00003##
[0009] wherein
[0010] R is hydrogen or methyl; and
[0011] Z is:
##STR00004##
[0012] or a pharmaceutically acceptable salt thereof.
[0013] The present invention also provides a compound of Formula
II:
##STR00005##
wherein X is N or CH, or a pharmaceutically acceptable salt
thereof.
[0014] The present invention also provides a method of treating
Alzheimer's disease in a patient in need of such treatment,
comprising administering to the patient an effective amount of a
compound of Formula I or II, or a pharmaceutically acceptable salt
thereof.
[0015] The present invention further provides a method of
preventing the progression of mild cognitive impairment to
Alzheimer's disease in a patient in need of such treatment,
comprising administering to the patient an effective amount of a
compound of Formula I or II, or a pharmaceutically acceptable salt
thereof.
[0016] The present invention also provides a method of treating
progressive supranuclear palsy in a patient in need of such
treatment, comprising administering to the patient an effective
amount of a compound of Formula I or II, or a pharmaceutically
acceptable salt thereof. The present invention also provides a
method of treating tau-mediated neurodegenerative disorders in a
patient, comprising administering to a patient in need of such
treatment an effective amount of a compound of Formula I or II, or
a pharmaceutically acceptable salt thereof.
[0017] Furthermore, this invention provides a compound of Formula I
or II, or a pharmaceutically acceptable salt thereof for use in
therapy, in particular for use in treating Alzheimer's disease or
for use in preventing the progression of mild cognitive impairment
to Alzheimer's disease. In addition, this invention provides a
compound of Formula I or II, or a pharmaceutically acceptable salt
thereof for use in treating progressive supranuclear palsy. The
invention also provides a compound of Formula I or II, or a
pharmaceutically acceptable salt thereof for use in treating
tau-mediated neurodegenerative disorders.
[0018] Even furthermore, this invention provides the use of a
compound of Formula I or II, or a pharmaceutically acceptable salt
thereof, for the manufacture of a medicament for treating
Alzheimer's disease or for preventing the progression of mild
cognitive impairment to Alzheimer's disease. In addition, this
invention provides the use of a compound of Formula I or II, or a
pharmaceutically acceptable salt thereof, for the manufacture of a
medicament for treating progressive supranuclear palsy. The
invention also provides the use of a compound of Formula I or II,
or a pharmaceutically acceptable salt thereof, for the manufacture
of a medicament for treating tau-mediated neurodegenerative
disorders.
[0019] The invention further provides a pharmaceutical composition,
comprising a compound of Formula I or II, or a pharmaceutically
acceptable salt thereof, with one or more pharmaceutically
acceptable carriers, diluents, or excipients. The invention further
provides a process for preparing a pharmaceutical composition,
comprising admixing a compound of Formula I or II, or a
pharmaceutically acceptable salt thereof, with one or more
pharmaceutically acceptable carriers, diluents, or excipients.
[0020] Mild cognitive impairment has been defined as a potential
prodromal phase of dementia associated with Alzheimer's disease
based on clinical presentation and on progression of patients
exhibiting mild cognitive impairment to Alzheimer's disease over
time. The term "preventing the progression of mild cognitive
impairment to Alzheimer's disease" includes restraining, slowing,
stopping, or reversing the progression of mild cognitive impairment
to Alzheimer's disease in a patient.
[0021] As used herein, the terms "treating" or "to treat" includes
restraining, slowing, stopping, or reversing the progression or
severity of an existing symptom or disorder.
[0022] As used herein, the term "patient" refers to a human.
[0023] As used herein, the term "effective amount" refers to the
amount or dose of compound of the invention, or a pharmaceutically
acceptable salt thereof which, upon single or multiple dose
administration to the patient, provides the desired effect in the
patient under diagnosis or treatment.
[0024] An effective amount can be determined by one skilled in the
art by the use of known techniques and by observing results
obtained under analogous circumstances. In determining the
effective amount for a patient, a number of factors are considered,
including, but not limited to: the species of patient; its size,
age, and general health; the specific disease or disorder involved;
the degree of or involvement or the severity of the disease or
disorder; the response of the individual patient; the particular
compound administered; the mode of administration; the
bioavailability characteristics of the preparation administered;
the dose regimen selected; the use of concomitant medication; and
other relevant circumstances. The compounds of the present
invention are effective at a dosage per day that falls within the
range of about 0.1 to about 15 mg/kg of body weight.
[0025] The compounds of the present invention are formulated as
pharmaceutical compositions administered by any route which makes
the compound bioavailable. Preferably, such compositions are for
oral administration. Such pharmaceutical compositions and processes
for preparing same are well known in the art (See, e.g., Remington:
The Science and Practice of Pharmacy, L. V. Allen, Editor,
22.sup.nd Edition, Pharmaceutical Press, 2012).
[0026] The compounds of Formula I and the pharmaceutically
acceptable salts thereof are particularly useful in the treatment
methods of the invention, with certain configurations being
preferred. The following list of compounds of the present invention
describe such configurations. It will be understood that these
preferences are applicable both to the treatment methods and to the
compounds of the invention.
[0027] Compounds of the present invention include:
##STR00006## ##STR00007##
wherein X is N or CH; and pharmaceutically acceptable salts
thereof.
[0028] The compound of Formula I wherein the methyl and oxygen
substituents on the pyrrolidine ring are in the cis or trans
configuration, or pharmaceutically acceptable salt thereof, are
included within the scope of the invention, with the cis
configuration being preferred. For example, one of ordinary skill
in the art will appreciate that the methyl at position 5 on the
pyrrolidine ring is in the cis configuration relative to the oxygen
at position 3 as shown in Scheme A below:
##STR00008##
[0029] In addition, one of ordinary skill in the art will
appreciate that the methyl at position 5 on the pyrrolidine ring is
in the trans configuration relative to the oxygen at position 3 as
shown in Scheme B below:
##STR00009##
[0030] It is preferred that when R is methyl, the methyl group may
be in the (R)-configuration or in the (S)-configuration, and it is
especially preferred that when R is methyl, the methyl group is in
the (S)-configuration.
[0031] Although the present invention contemplates all individual
enantiomers and diasteromers, as well as mixtures of the
enantiomers of said compounds, including racemates, the compound of
Formula Ia and pharmaceutically acceptable salts thereof is
preferred.
[0032] Individual enantiomers may be separated or resolved by one
of ordinary skill in the art at any convenient point in the
synthesis of compounds of the invention, by methods such as
selective crystallization techniques, chiral chromatography (See
for example, J. Jacques, et al., "Enantiomers, Racemates, and
Resolutions", John Wiley and Sons, Inc., 1981, and E. L. Eliel and
S. H. Wilen, "Stereochemistry of Organic Compounds",
Wiley-Interscience, 1994), or supercritical fluid chromatography
(SFC) (See for example, T. A. Berger; "Supercritical Fluid
Chromatography Primer," Agilent Technologies, July 2015).
[0033] A pharmaceutically acceptable salt of the compounds of the
invention can be formed, for example, by reaction of an appropriate
free base of a compound of the invention and an appropriate
pharmaceutically acceptable acid in a suitable solvent under
standard conditions well known in the art. See, for example, Gould,
P. L., "Salt selection for basic drugs," International Journal of
Pharmaceutics, 33: 201-217 (1986); Bastin, R. J., et al. "Salt
Selection and Optimization Procedures for Pharmaceutical New
Chemical Entities," Organic Process Research and Development, 4:
427-435 (2000); and Berge, S. M., et al., "Pharmaceutical Salts,"
Journal of Pharmaceutical Sciences, 66: 1-19, (1977).
[0034] The compounds of the present invention, or salts thereof,
may be prepared by a variety of procedures known to one of ordinary
skill in the art, some of which are illustrated in the schemes,
preparations, and examples below. The products of each step in the
schemes below can be recovered by conventional methods well known
in the art, including extraction, evaporation, precipitation,
chromatography, filtration, trituration, and crystallization. In
the schemes below, all substituents unless otherwise indicated, are
as previously defined. The reagents and starting materials are
readily available to one of ordinary skill in the art. Without
limiting the scope of the invention, the following schemes,
preparations, and examples are provided to further illustrate the
invention. In addition, one of ordinary skill in the art
appreciates that compounds of Formula I may be prepared by using
starting material or intermediate with the corresponding desired
stereochemical configuration which can be prepared by one of skill
in the art.
[0035] Certain abbreviations are defined as follows: "ACN" refers
to acetonitrile; "Ac" refers to acetyl; "AcOH" refers to acetic
acid; "Ac.sub.2O" refers to acetic anhydride; "BOC" refers to
tert-butoxycarbonyl; "CBz" refers to carbonylbenzyloxy; "DCM"
refers to methylene chloride or dichloromethane; "DIPEA" refers to
diisopropylethylamine; "DMEA" refers to dimethylethylamine; "DMF"
refers to N,N-dimethylformamide; "DMSO" refers to dimethyl
sulfoxide; "dppf" refers to diphenylphosphinoferrocene; "EDTA"
refers to ethylenediaminetetraacetic acid; "ES/MS" refers to
Electrospray Mass Spectrometry; "EtOAc" refers to ethyl acetate;
"EtOH" refers to ethanol or ethyl alcohol; "h" refers to hour or
hours; "IPA" refers to isopropanol or isopropyl alcohol; "JohnPhos"
refers to 2-(di-tert-butylphosphino)biphenyl; "KO-t-Bu" refers to
potassium-tert-butoxide; "Me" refers to methyl; "min" refers to
minute or minutes; "MTBE": refers to methyl tert-butyl ether;
"NADP" refers to .beta.-nicotinamide adenine dinucleotide phosphate
disodium salt; "NaO-t-Bu" refers to sodium-tert-butoxide; "OAc"
refers to acetate or acetoxy; "RT" refers to room temperature;
"TEA" refers to triethylamine; "TFA" refers to trifluoroacetic
acid; "THF" refers to tetrahydrofuran; "TMEDA" refers to
tetramethylethylenediamine; "Tris" refers to
tris(hydroxymethyl)aminomethane or
2-amino-2-(hydroxymethyl)propane-1,3-diol; "[.alpha.].sub.D.sup.20"
refers to specific optical rotation at 20.degree. C. and 589 nm,
wherein c is the concentration in g/mL.
##STR00010##
[0036] Scheme 1 illustrates the synthesis of the compounds of
Formula II. In Scheme 1, step A, the pyrrolo-nitrogen of the
appropriate 2-chloro-6,7-dihydro-5H-pyrrolopyrimidine hydrochloride
(X=N) or 2-chloro-6,7-dihydro-5H-pyrrolopyridine hydrochloride
(X=CH) may be acylated under a wide variety of acylating agents
well known to the skilled artisan. For example, about 1 equivalent
of 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
(X=N) or 2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine
hydrochloride (X=CH) may be dissolved in an appropriate organic
solvent, such as DCM, about 4 equivalents of a suitable
non-nucleophilic base, such as TEA, pyridine, or DIPEA, may be
added, and the mixture may be treated dropwise with the addition of
about 1.1 equivalents of acetyl chloride for about 15 to 20 h at
RT. The resulting reaction product may be isolated by techniques
well known in the art, such as extraction and chromatography. For
example, the acylation reaction may be quenched with a suitable
mild aqueous base, such as NaHCO.sub.3, Cs.sub.2CO.sub.3, or
KHCO.sub.3, the resulting biphasic may be extracted with a suitable
organic solvent, such as DCM, and the combined organic extracts may
be washed sequentially with water, saturated aqueous NaCl, dried
over a suitable drying agent, such as Na.sub.2SO.sub.4 or
MgSO.sub.4, filtered, and the filtrate may be concentrated under
reduced pressure. The resulting residue may be purified by flash
chromatography over silica, using a suitable mixture of polar and
non-polar organic solvents, such as EtOAc or acetone in hexanes, to
obtain the desired acylated product of Scheme 1, step A.
[0037] In Scheme 1, step B, nucleophilic aromatic substitution with
an appropriately N-protected commercially available
hydroxypyrrolidine is well known in the art. The skilled artisan
will recognize that a wide array of nucleophilically-stable
N-protecting groups may be used, such as Boc, CBz, benzyl, or
methyl, as needed for ease of removal. For example, about 1
equivalent of the appropriately N-protected
4-hydroxy-2-methylpyrrolidine may be treated with about 2
equivalents of a suitable strong base, such as NaH, KO-t-Bu, or
NaO-t-Bu, in an suitable polar solvent, such as THF, DMF,
1,4-dioxane, or DMSO, at about 0.degree. C. to about RT. About 1.2
equivalents of the desired acylated product of Scheme 1, step A,
may be added at about 0.degree. C. to about RT, and the resulting
mixture may be stirred at about RT for about 12-24 h. The resulting
reaction product may be isolated by techniques well known in the
art, such as extraction and chromatography. For example, the
reaction mixture may be diluted with water, extracted with an
appropriate organic solvent, such as DCM or EtOAc, and the combined
organic extracts may be washed sequentially with water, saturated
aqueous NaCl, dried over a suitable drying agent, such as
Na.sub.2SO.sub.4 or MgSO.sub.4, filtered, and the filtrate may be
concentrated under reduced pressure. The resulting residue may be
purified by flash chromatography over silica, using a suitable
mixture of polar and non-polar organic solvents, such as EtOAc or
acetone in hexanes, to obtain the desired product of Scheme 1, step
B. The skilled artisan will recognize that different isomers (e.g.,
cis- or trans-) of the commercially available hydroxypyrrolidine
will give different isomers of the product of Scheme 1, step B.
[0038] In Scheme 1, step C, the skilled artisan will recognize the
removal of the protecting group may be accomplished under an array
of conditions well known in the art. For example, wherein PG=BOC,
the product of Scheme 1, step B may be dissolved in a suitable
organic solvent, such as DCM, and treated with an appropriate acid,
such as HCl dissolved in an organic solvent (e.g., Et.sub.2O,
1,4-dioxane), or TFA, and the resulting reaction mixture may be
stirred at about RT to about 80.degree. C. from about 30 min to 8
h. The resulting reaction product may be isolated by techniques
well known in the art, such as evaporation. For example, the
reaction mixture may be subjected to concentration under reduced
pressure to obtain the HCl salt of the product of Scheme 1, step
C.
[0039] In Scheme 1, step D, N--C bond formation may be accomplished
under a variety of methods well known in the art, including
nucleophilic displacement of an alkyl halide, transition-metal
catalysis, or under reductive amination conditions. For example,
about 1 equivalent of an appropriately substituted aldehyde, such
as 6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde and about 1
equivalent of the deprotected pyrrolidine hydrochloride (the
product of Scheme 1, step C) may be dissolved in a suitable organic
solvent, such as DCM, and the resulting solution may be treated
with about 2.5-2.75 equivalents of a non-nucleophilic base, such as
DIPEA or TEA for about 30 min to about 1 h. About 3 equivalents of
a suitable borohydride reducing agent, such as sodium borohydride,
sodium tri(acetoxy)borohydride, or sodium cyanoborohydride, may be
added, and the resulting mixture may be stirred at about RT for
about 12 to 24 h. The resulting reaction product may be isolated by
techniques well known in the art, such as extraction and column
chromatography. For example, the reaction mixture may be quenched
slowly with a saturated aqueous mild basic solution, such as
NaHCO.sub.3. The resulting mixture may be extracted with a suitable
organic solvent, such as DCM or EtOAc, and the combined organic
extracts may be washed sequentially with water, saturated aqueous
NaCl, dried over a suitable drying agent, such as Na.sub.2SO.sub.4
or MgSO.sub.4, filtered, and the filtrate may be concentrated under
reduced pressure. The resulting residue may be purified by flash
chromatography over silica, using a suitable mixture of polar and
non-polar organic solvents, such as EtOAc or acetone in hexanes, or
methanol in DCM or EtOAc, to obtain the compound of Formula II.
##STR00011##
[0040] Scheme 2 illustrates the preparation of the requisite
6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde. In Scheme 2,
step A, the skilled artisan will recognize that
5-bromo-2,4-difluoroaniline may be acylated by treatment with a
suitable acylating reagent, such as Ac.sub.2O or AcCl, at RT and
heated to about 60.degree. C., to obtain the acylated aniline. For
example, about 1 equivalent of 5-bromo-2,4-difluoroaniline may be
added to about 11 equivalents of Ac.sub.2O and the resulting
mixture may be heated to about 60.degree. C. with stirring for
about 10 min. The resulting mixture may be concentrated under
reduced pressure, agitated in heptane, and the resulting solid
collected by filtration to obtain
N-(5-bromo-2,4-difluoro-phenyl)acetamide, the product of Scheme 2,
step A.
[0041] In Scheme 2, step B, the amide may be converted to the
thioamide under a variety of conditions well known in the art, such
as with elemental sulfur, Lawesson's Reagent, or ammonium
phosphorodithioate, in a suitable organic solvent. More
specifically, about 1 equivalent of
N-(5-bromo-2,4,-difluoro-phenyl)acetamide may be treated with about
0.5 equivalents of
pyridin-1-ium-1-yl-[pyridin-1-ium-1-yl(sulfido)phosphinothioyl]sulfanyl-s-
ulfido-thioxo-phosphane (see, for example, J. Org. Chem. 2011, 76,
1546-1553) in ACN and stirred at 85.degree. C. overnight. The
reaction mixture may be concentrated under reduced pressure, the
resulting residue dissolved in EtOAc, and the mixture may be washed
with saturated aqueous NaCl, dried over Na.sub.2SO.sub.4, filtered,
and the filtrate concentrated under reduced pressure to obtain
N-(5-bromo-2,4-difluoro-phenyl)thioacetamide, the product of Scheme
2, step B, as a crude oil, suitable for use without additional
purification.
[0042] In Scheme 2, step C, one skilled in the art may recognize
that N-(5-bromo-2,4-difluoro-phenyl)thioacetamide may be cyclized
to the benzothiazole by addition of the appropriate base, such as
NaH, Cs.sub.2CO.sub.3, or NaO-t-Bu, in a polar aprotic solvent such
as DMF, DMSO, or ACN. More specifically, about 1 equivalent of
thioamide may be treated with a slight excess of NaO-t-Bu in DMF
and heated to about 40.degree. C. with stirring overnight. The
product may be isolated utilizing extraction techniques as are
common to one skilled in the art. For example, the concentrated
reaction mixture may be dissolved in EtOAc, washed with H.sub.2O
and saturated aqueous NaCl, dried over MgSO.sub.4, filtered, and
concentrated to provide the benzothiazole product of Scheme 2, step
C.
[0043] In Scheme 2, step D, benzothiazole may undergo carbonylation
of the site bearing the bromine as is well described in the art,
using an array of palladium catalysts, including PdCl.sub.2,
Pd(OAc).sub.2, or Pd.sub.2(dba).sub.3, ligands including PPh.sub.3,
PBu.sub.3, dppf, or JohnPhos, and carbonyl sources, such as CO,
CO/H.sub.2, HCOOLi, HCOOK, in a polar aprotic solvent, such as ACN,
DMSO, or DMF. More specifically, about 2 equivalents of HCOOK may
be added to a reaction mixture containing about 0.05-0.15
equivalents Pd(OAc).sub.2, about 0.05-0.15 equivalents of a
suitable phosphine ligand, such as JohnPhos, about 1.2 equivalents
1,1,3,3-tetramethylbutyl isocyanide, and about 1 equivalent
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole dissolved in a suitable
polar solvent, such as DMF. The reaction mixture may be heated to
about 65.degree. C., stirred overnight, cooled to RT, and the crude
aldehyde product of the palladium-mediated reaction may be isolated
and purified utilizing techniques well known in the art. For
example, the residue may be dissolved in EtOAc, washed sequentially
with saturated aqueous Na.sub.2CO.sub.3 and saturated aqueous NaCl,
and purified using silica gel chromatography with a gradient of a
mixture of suitable organic solvents, such as heptane:EtOAc, to
obtain the desired carbonylated benzothiazole, the product of
Scheme 2, step D.
##STR00012##
[0044] In Scheme 3, step A,
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole is combined with about
0.03 equivalents of a suitable palladium catalyst, such as
[1,3-bis(diphenylphosphino)propane]palladium (II) dichloride in a
suitable solvent, such as ethylene glycol, and about 3 equivalents
of trimethylamine under nitrogen. About 5 equivalents of
1-vinyloxybutane are added to the mixture and the reaction is
heated at about 100.degree. C. for about 18 hours. After cooling to
RT, the reaction is treated with excess aqueous HCl and the
product, 1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone, is
isolated using standard extraction techniques well know in the
art.
[0045] In Scheme 3, step B,
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone is converted to
(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanol using a
catalytic amount of (R)-Rucy-xylBinap (CAS #1384974-38-2) and about
0.04 equivalents of potassium tert-butoxide in a suitable solvent,
such as toluene, in an autoclave. The autoclave is cooled to about
-10.degree. C. and charged to about 450 psi with hydrogen with
stirring for about 4.5 hours. The reaction is then warmed to RT and
stirred for about 15 hours, then concentrated, and the product of
step B is isolated by techniques well known in the art, such as
flash chromatography.
[0046] In Scheme 3, step C,
(S)-1-(6-fluoro-2-methylbenzo[d]thiazol-5-yl)ethan-1-ol is
dissolved in a suitable solvent, such as dioxane and treated with
about 0.5 equivalents of 1-formylpyrrolidine and about 2.5
equivalents of benzoyl chloride. After stirring for about 36 hours
at room temperature, the reaction mixture is cooled to about
0.degree. C., diluted with ethyl acetate and about 1.5 equivalents
of N,N-dimethylethylenediamine is added dropwise to the mixture.
The mixture is then warmed to RT, added to excess saturated aqueous
citric acid solution, and the desired product,
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole,
isolated by standard extraction techniques followed by purification
via flash chromagraphy.
[0047] In Scheme 3, step D, the appropriately substituted
pyrrolidine is dissolved in a suitable solvent, such as
acetonitrile, treated with about 0.8 equivalents of
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole and
excess cesium carbonate, and stirred for about 21 hours at about
68.degree. C. The product of Formula I wherein R is methyl is then
isolated and purified under conditions well known in the art.
##STR00013##
[0048] In Scheme 4, steps A through D are carried out in a manner
essentially analogous to those described above in Scheme 1, Steps A
through D.
##STR00014##
[0049] In Scheme 5, steps A through D are carried out in a manner
essentially analogous to those described above in Scheme 1, Steps A
through D.
PREPARATIONS AND EXAMPLES
[0050] The following Preparations and Examples further illustrate
the invention and represent typical synthesis of the compound of
the invention. The reagents and starting materials are readily
available or may be readily synthesized by one of ordinary skill in
the art. It should be understood that the Preparations and Examples
are set forth by way of illustration and not limitation, and that
various modifications may be made by one of ordinary skill in the
art.
[0051] LC-ES/MS is performed on an AGILENT.COPYRGT.HP1100 liquid
chromatography system. Electrospray mass spectrometry measurements
(acquired in positive and/or negative mode) are performed on a Mass
Selective Detector quadrupole mass spectrometer interfaced to the
HP1100 HPLC. LC-MS conditions (low pH): column: PHENOMENEX.COPYRGT.
GEMINI.COPYRGT. NX C18 2.1.times.50 mm 3.0 .mu.m; gradient: 5-100%
B in 3 min, then 100% B for 0.75 min column temperature: 50.degree.
C.+/-10.degree. C.; flow rate: 1.2 mL/min; Solvent A: deionized
water with 0.1% HCOOH; Solvent B: ACN with 0.1% formic acid;
wavelength 214 nm. Alternate LC-MS conditions (high pH): column:
XTERRA.COPYRGT.MS C18 columns 2.1.times.50 mm, 3.5 .mu.m; gradient:
5% of solvent A for 0.25 min, gradient from 5% to 100% of solvent B
in 3 min and 100% of solvent B for 0.5 min or 10% to 100% of
solvent B in 3 min and at 100% of solvent B for 0.75 min; column
temperature: 50.degree. C.+/-10.degree. C.; flow rate: 1.2 mL/min;
Solvent A: 10 mM NH.sub.4HCO.sub.3 pH 9; Solvent B: ACN;
wavelength: 214 nm.
[0052] NMR spectra are performed on a Bruker AVIII HD 400 MHz NMR
Spectrometer, obtained as CDCl.sub.3 or DMSO solutions reported in
ppm, using residual solvent [CDCl.sub.3, 7.26 ppm;
(CD.sub.3).sub.2SO, 2.05 ppm] as reference standard. When peak
multiplicities are reported, the following abbreviations may be
used: s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet), br-s (broad singlet), dd (doublet of doublets), dt
(doublet of triplets). Coupling constants (J), when reported, are
reported in hertz (Hz).
Preparation 1
1-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)ethan-1-one
##STR00015##
[0054] Scheme 1, step A (X=N): To a 0.degree. C. solution of
2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine HCl (10.4 g, 54.2
mmol) in DCM (250 mL) is dropwise added TEA (37 mL, 265 mmol) and
acetyl chloride (5.2 mL, 73 mmol). The reaction mixture is stirred
at RT for 19 h. The reaction mixture is diluted with DCM (50 mL)
and saturated aqueous NaHCO.sub.3 solution (200 mL). The aqueous
layer is extracted with DCM (2.times.100 mL). The combined organic
extracts are washed with saturated aqueous NaCl, dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure. The
resulting residue is dissolved in DCM, adsorbed onto diatomaceous
earth, and purified via flash chromatography over silica gel,
eluting with a gradient of 50-100% acetone in hexanes, to obtain
the title compound after solvent evaporation of the desired
chromatographic fractions (5.17 g, 48% yield). ES/MS m/z: 198
(M+H).
Alternative Procedure for Preparation 1
[0055] 2-Chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine
hydrochloride (32.0 g, 167 mmol; see WO17/071636) is ground to a
fine powder with a mortar and pestle. The powder is transferred
into a flask and DCM (320 mL) and pyridine (35.0 mL, 433 mmol) are
added at RT. The reaction mixture is stirred vigorously in an
ice-water bath and acetyl chloride (15.5 mL, 217 mmol) is added
dropwise over 10 min, maintaining an internal temperature below
10.degree. C. during the addition. The reaction mixture is stirred
vigorously at RT for 2 h, then stirred in an ice-water bath, and
aqueous 2M HCl solution (320 mL) is added over 5 min, maintaining
an internal temperature below 15.degree. C. during the addition.
The mixture is stirred at RT for 10 min, and is filtered through a
short pad of diatomaceous earth, washing with DCM (50 mL) and water
(50 mL). The filtrate is transferred to a separating funnel and the
layers are separated. The aqueous layer is extracted with DCM
(3.times.300 mL), and the combined organics are dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The
resulting residue is suspended in 50% cyclopentyl-methyl
ether/heptane (300 mL) and the mixture is stirred vigorously in a
50.degree. C. heating block for 30 minutes. The mixture is stirred
at RT for 30 min and is filtered. The filtered solid is dried under
vacuum at 40.degree. C. overnight to obtain the title compound
(29.38 g, 88% yield) as a pale brown solid. ES/MS m/z: 198
(M+H).
Preparation 2
tert-butyl
(2S,4R)-4-((6-acetyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-y-
l)oxy)-2-methylpyrrolidine-1-carboxylate
##STR00016##
[0057] Scheme 1, step B (X=N): To a solution of tert-butyl
(2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (2.07 g, 10.3
mmol) and THE (20 mL) at 0.degree. C. is added 60% mass NaH in
mineral oil (0.83 g, 20.7 mmol) in one portion and the mixture
stirred for 25 min.
1-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)ethan-1-one
(2.5 g, 12.7 mmol) and additional THE (5 mL) is added, the mixture
is allowed to warm slowly to RT over 45 min, and the mixture is
stirred at RT for 19 h. The reaction mixture is diluted with water
(75 mL) and EtOAc (75 mL). The aqueous layer is extracted with
EtOAc (2.times.50 mL), and the combined organic extracts are dried
over MgSO.sub.4, filtered, and concentrated under reduced pressure.
The resulting residue is dissolved in DCM and purified via flash
chromatography over silica gel, eluting with a gradient of 50-90%
acetone in hexanes, to obtain the title compound after solvent
evaporation of the desired chromatographic fractions (3.07 g, 82%
yield). ES/MS m/z: 307 (M+H--C.sub.4H.sub.9).
Alternative Procedure for Preparation 2
[0058] To a flask is added 60% NaH in mineral oil (5.37 g, 134
mmol) and THF (54 mL) at RT. The flask is stirred in an ice-water
bath and a solution of tert-butyl
(2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (13.5 g, 67.1
mmol, see J. Med. Chem. 1988, 31, 1598-1611) in THE (54 mL) is
added over 5 min, maintaining an internal temperature below
10.degree. C. during the addition. The reaction mixture is stirred
at RT for approximately 15 min and subsequently in a 41.degree. C.
heating block for approximately 10 min. To the mixture is added a
slurry of
1-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)ethan-1-one
(20.1 g, 101 mmol) in THE (297 mL) dropwise with a peristaltic pump
over 1 h. The reaction mixture is stirred in a 40.degree. C.
heating block overnight, cooled to 0.degree. C. in an ice-water
bath, and saturated aqueous NH.sub.4Cl solution (120 mL) is added
over 5 min. 2-Methyltetrahydrofuran (10 mL) is added. The mixture
is stirred at RT for 5 min, is transferred to a separating funnel,
and the layers are separated. The aqueous layer is extracted with
2-methyltetrahydrofuran (130 mL) and the combined organic extracts
are dried over Na.sub.2SO.sub.4, filtered, and the filtrate is
concentrated under reduced pressure to give the title compound
(35.2 g, >99% yield) as a dark red/brown oil. ES/MS m/z: 385
(M+Na).
Preparation 3
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]p-
yrimidin-6-yl)ethan-1-one hydrochloride
##STR00017##
[0060] Scheme 1, step C (X=N): To a solution of tert-butyl
(2S,4R)-4-((6-acetyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)oxy)-2-m-
ethylpyrrolidine-1-carboxylate (1.8 g, 5 mmol) in DCM (25 mL) is
added a 4M solution of HCl in 1,4-dioxane (6.2 mL, 25 mmol). The
resulting mixture is stirred at RT for 4 h. The resulting
suspension is concentrated under reduced pressure and the resulting
residue is placed under vacuum for 1 h to obtain the title compound
(1.48 g, >99% yield). ES/MS m/z: 263 (M+H).
Preparation 4
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]p-
yrimidin-6-yl)ethan-1-one
##STR00018##
[0062] To a flask is added tert-butyl
(2S,4R)-4-[(6-acetyl-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl)oxy]-2-methy-
l-pyrrolidine-1-carboxylate (35.23 g, 67.1 mmol) and isopropyl
acetate (176 mL). The reaction mixture is stirred in an ice-water
bath (internal temperature 10.degree. C.) and an aqueous 5M
solution of HCl (176 mL, 880 mmol) is added dropwise over 5 min,
maintaining an internal temperature below 15.degree. C. during the
addition. The reaction mixture is stirred at RT for 1 h, the
mixture is transferred to a separating funnel with ethyl acetate (5
mL) and water (5 mL), and the layers are separated. The aqueous
layer is cooled in an ice-water bath and DCM (180 mL) and water
(180 mL) are added. The mixture is stirred vigorously and solid
potassium phosphate monohydrate (185 g, 803.37 mmol) is added over
5 min. The mixture is stirred at RT for 5 min, passed through a
short pad of diatomaceous earth, washing with DCM (50 mL) and water
(50 mL), and the layers are separated. To the aqueous layer is
added solid potassium phosphate monohydrate (23.2 g, 101 mmol), the
mixture is stirred at RT for 5 min, and the mixture is extracted
with DCM (3.times.180 mL). The combined organics are dried over
Na.sub.2SO.sub.4 and concentrated under reduced pressure to give
the title compound (18.23 g, 67% yield) as a brown foamy solid.
ES/MS m/z: 263 (M+H).
Preparation 5
1-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one
##STR00019##
[0064] Scheme 1, step A (X=CH): To a 0.degree. C. solution of
2-chloro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine hydrochloride (1.0
g, 5.2 mmol) in DCM (13 mL) is dropwise added DIPEA (3.6 mL, 21
mmol) and acetyl chloride (0.4 mL, 6 mmol). The reaction mixture is
stirred at RT for 24 h. The resulting mixture is diluted with DCM
(20 mL) and saturated aqueous NaHCO.sub.3 (30 mL). The aqueous
layer is extracted with DCM (2.times.30 mL). The combined organic
extracts are dried over MgSO.sub.4, filtered, and concentrated
under reduced pressure. The resulting residue is dissolved in DCM,
adsorbed onto diatomaceous earth, and purified via flash
chromatography over silica gel, eluting with a gradient of 50-100%
acetone in hexanes, to obtain the title compound after solvent
evaporation of the desired chromatographic fractions (0.95 g, 92%
yield). ES/MS m/z: 197 (M+H).
Preparation 6
tert-butyl(2S,4R)-4-((6-acetyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)o-
xy)-2-methylpyrrolidine-1-carboxylate
##STR00020##
[0066] Scheme 1, step B (X=CH): To a solution of tert-butyl
(2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (0.41 g, 2.03
mmol),
1-(2-chloro-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one
(0.47 g, 2.36 mmol), and THE (8 mL) at RT is portion wise added
KO-t-Bu (0.45 g, 4 mmol) and the mixture is stirred at 50.degree.
C. for 4.5 h. The reaction mixture is diluted with water (50 mL)
and EtOAc (50 mL). The aqueous layer is extracted with EtOAc
(2.times.50 mL), and the combined organic extracts are dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure. The
resulting residue is dissolved in DCM and purified via flash
chromatography over silica gel, eluting with a gradient of 40-100%
acetone in hexanes, to obtain the title compound after solvent
evaporation of the desired chromatographic fractions (0.34 g, 47%
yield). ES/MS m/z: 262 (M+H--C.sub.4H.sub.9).
Preparation 7
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]p-
yridin-6-yl)ethan-1-one hydrochloride
##STR00021##
[0068] Scheme 1, step C (X=CH): To a solution of tert-butyl
(2S,4R)-4-((6-acetyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-2-yl)oxy)-2-met-
hylpyrrolidine-1-carboxylate (0.34 g, 0.94 mmol) in DCM (5.0 mL) is
added a 4M solution of HCl in 1,4-dioxane (1.2 mL, 4.8 mmol). The
resulting mixture is stirred at RT for 3 h. The resulting
suspension is concentrated under reduced pressure, and the
resulting residue is placed under vacuum for 1 h to obtain the
title compound (0.28 g, >99% yield). ES/MS m/z: 262 (M+H).
Preparation 8
N-(5-bromo-2,4-difluoro-phenyl)acetamide
##STR00022##
[0070] Scheme 2, step A: To a flask is added Ac.sub.2O (389 mL)
with stirring in a heating block at about 61.degree. C. (internal
temperature 60.degree. C.). To the flask is added
5-bromo-2,4-difluoroaniline (77.7 g, 374 mmol) portion wise over 30
min, maintaining an internal temperature below 65.degree. C. during
the addition. The reaction mixture is stirred in a heating block at
about 61.degree. C. for 10 min. and cooled to RT to give a residue
which is concentrated from toluene (4.times.200 mL) to give a pale
brown/pink solid. The concentrated solid is suspended in heptane
(80 mL) and the mixture is agitated on a rotary evaporator in a
50.degree. C. water bath for 15 min at atmospheric pressure, cooled
to RT, and filtered. The filtered solid is collected and dried
under vacuum at 40.degree. C. for 2 h to obtain the title compound
(89.6 g, 95% yield) as an off-white solid. ES/MS m/z: 250
(M+H).
Preparation 9
N-(5-bromo-2,4-difluoro-phenyl)thioacetamide
##STR00023##
[0072] Scheme 2, step B: To a solution of
N-(5-bromo-2,4-difluoro-phenyl)acetamide (89.6 g, 358 mmol) in
anhydrous ACN (896 mL) is added
pyridin-1-ium-1-yl-[pyridin-1-ium-1-yl(sulfido)phosphinothioyl]sulfanyl-s-
ulfido-thioxo-phosphane (68.2 g, 179 mmol, J. Org. Chem. 2011, 76,
1546-1553) at RT. The slurry is stirred in a 85.degree. C. heating
block overnight (internal temperature 80.degree. C.), cooled to RT,
and poured into a mixture of ice (200 g) and saturated aqueous NaCl
(700 mL). The mixture is diluted with EtOAc (900 mL) stirred at RT
for 10 min, the layers are separated, and the aqueous layer
additionally extracted with EtOAc (900 mL). The combined organic
extracts are washed with saturated aqueous NaCl solution (900 mL),
dried over Na.sub.2SO.sub.4, and concentrated under reduced
pressure to give the title compound as a dark brown oil, which is
dissolved in DMF (953 mL) at RT, and used without additional
purification.
Preparation 10
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole
##STR00024##
[0074] Scheme 2, step C: To a DMF solution of
N-(5-bromo-2,4-difluoro-phenyl)thioacetamide is added NaO-t-Bu
(42.6 g, 430 mmol) portion wise over 20 min with stirring,
maintaining an internal temperature below 30.degree. C. The
reaction mixture is stirred at RT for 5 min, stirred overnight in a
42.degree. C. heating block (internal temperature 40.degree. C.),
and cooled to RT. The reaction mixture is added dropwise to a
mixture of ice (250 g) and H.sub.2O (700 mL) over 5 min,
maintaining an internal temperature below 20.degree. C. The mixture
is stirred at RT for 10 min and filtered. The filtered solid is
dried under vacuum at 40.degree. C. overnight, and suspended in 50%
MeOH/H.sub.2O (480 mL). The mixture is stirred in a 45.degree. C.
heating block for 15 min, cooled to RT, and filtered. The filtered
solid is dried under vacuum at 40.degree. C. for 72 h to give a
pale brown solid. The material is combined with EtOAc (700 mL) and
the mixture is stirred at RT for 10 min, H.sub.2O (700 mL) is
added, and the layers separated. The aqueous layer is extracted
with EtOAc (700 mL), then the combined organic extracts are washed
with saturated aqueous NaCl (700 mL), dried over MgSO.sub.4, and
concentrated under reduced pressure to give the title compound
(62.7 g, 71% yield) as a brown solid. .sup.1H NMR (d.sub.6-DMSO)
.delta.: 2.82 (s, 3H), 7.57 (m, 1H), 8.12 (m, 1H).
Preparation 11
6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde
##STR00025##
[0076] Scheme 2, step D:
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole (100.9 g, 410 mmol) in
DMF (1009 mL) is sparged with N.sub.2 for 5 min at RT with
stirring. Potassium formate (52.3 g, 615.0 mmol), palladium(II)
acetate (2.82 g, 12.30 mmol), 2-(di-tert-butylphosphino)biphenyl
(5.19 g, 17.2 mmol) and 1,1,3,3-tetramethylbutyl isocyanide (90.8
mL, 492.0 mmol) are added and the mixture is sparged with N.sub.2
for 30 min at RT with stirring. The reaction mixture is stirred
overnight at an internal temperature of 65.degree. C., cooled to
20-25.degree. C., and 2M aqueous HCl solution (820 mL) is added
dropwise over 30 min, maintaining an internal temperature below
30.degree. C. The resulting mixture is stirred at 20-25.degree. C.
for 2 h and diluted with EtOAc (1.5 L) and H.sub.2O (1 L). The
layers are separated and the organic layer is washed with 10%
aqueous N-acetyl-cysteine solution (2.times.1 L), saturated aqueous
Na.sub.2CO.sub.3 (750 mL.times.2) and saturated aqueous NaCl (750
mL); the organic extract is dried over MgSO.sub.4 and concentrated
under reduced pressure to provide the first batch of crude
material. The aqueous HCl layer from the first extraction is
further extracted with EtOAc (1 L, then 500 mL), and the combined
organic extracts are washed with saturated aqueous NaCl (500 mL),
dried over MgSO.sub.4, and concentrated under reduced pressure to
provide the second batch of crude material. The combined aqueous
N-acetyl-cysteine layers are then extracted with EtOAc (1 L, then
500 mL) and the combined organic extracts are washed sequentially
with saturated aqueous Na.sub.2CO.sub.3 (500 mL) and saturated
aqueous NaCl (500 mL); the combined organic extracts are dried over
MgSO.sub.4 and concentrated under reduced pressure to provide the
third batch of crude material. The three batches of crude material
are combined in MTBE (250 mL) and heptane (250 mL) and the
resulting slurry is stirred at RT for 20 min. The resulting
precipitate is filtered and washed with heptane (250 mL). The
filtered solid is dried under vacuum at 45.degree. C. to give a
first batch of product. The filtrate is concentrated and the
residue is purified by column chromatography over silica, eluting
with a gradient of 0-100% EtOAc/heptane. The product-containing
fractions are combined and concentrated to a volume of
approximately 400 mL, the resulting slurry is stirred at RT for 15
min, filtered, and the filtered solid is washed with heptane (200
mL), to give a second batch of product. The first and second
batches of product are combined with heptane (500 mL), slurried at
RT, filtered, and the filtered solid is washed with heptane (250
mL). The filtered solid is dried under vacuum at 45.degree. C.
overnight to give the title compound (63.5 g, 79% yield). ES/MS
m/z: 196 (M+H).
Preparation 12
1-(6-chloro-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)ethanone
##STR00026##
[0078] Scheme 4, step A: To a scintillation vial is added
6-chloro-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine; hydrochloride (1.6
g, 8.4 mmol), dichloromethane (21 mL) and N,N-diisopropylethylamine
(6 mL, 34 mmol). The mixture is capped, cooled to 0.degree. C. in
an ice bath and acetyl chloride (0.7 mL, 10 mmol) is added
dropwise. The reaction mixture is removed from ice bath and is
stirred at room temperature for 24 h. Saturated aqueous sodium
bicarbonate solution (20 mL) and water (5 mL) is added and stirred
5 minutes. The organic layer is removed. The aqueous layer is
extracted with dichloromethane (2.times.10 mL). The combined
organic phases are dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. The residue is dissolved in
dichloromethane, loaded on silica cartridge and purified via flash
chromatography eluting with hexanes:acetone [60:40 to 0:100] to
give the title compound
1-(6-chloro-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)ethanone (1.51 g,
7.7 mmol, 91% yield). ES/MS m/z: 197 (M+H).
Preparation 13
Tert-butyl(2S,4R)-4-[(2-acetyl-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl)oxy]--
2-methyl-pyrrolidine-1-carboxylate
##STR00027##
[0080] Scheme 4, step B: To a scintillation vial is added
tert-butyl (2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate
(0.3 g, 1.49 mmol),
1-(6-chloro-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)ethanone (0.35 g,
1.78 mmol) and tetrahydrofuran (6 mL). Mixture is stirred at RT to
give a white suspension. Potassium tert-butoxide (0.35 g, 3.09
mmol) is added portion wise. The mixture is capped and is heated at
45.degree. C. for 5 hours. The mixture poured into a separatory
funnel containing water (30 mL) and ethyl acetate (30 mL). The
organic layer is separated and aqueous phase extracted with ethyl
acetate (2.times.30 mL). The combined organic phase is dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure. The residue is purified via flash chromatography to give
the title compound tert-butyl
(2S,4R)-4-[(2-acetyl-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl)oxy]-2-methyl--
pyrrolidine-1-carboxylate (0.121 g, 0.334 mmol, 22% yield). ES/MS
m/z: 306 (M+H--C.sub.4H.sub.9).
Preparation 14
1-[6-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]pyridin-
-2-yl]ethanone; hydrochloride
##STR00028##
[0082] Scheme 4, step C: To a solution of tert-butyl
(2S,4R)-4-[(2-acetyl-1,3-dihydropyrrolo[3,4-c]pyridin-6-yl)oxy]-2-methyl--
pyrrolidine-1-carboxylate (0.120 g, 0.332 mmol) in dichloromethane
(3 mL) is added hydrochloric acid in 1,4-dioxane (0.4 mL, 2 mmol, 4
M solution). The mixture is stirred at room temperature for 3 h.
The suspension is concentrated under reduced pressure and the
residue is placed under vacuum for 1 h to give
1-[6-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]pyridi-
n-2-yl]ethanone; hydrochloride (0.099 g, 0.299 mmol, 100% yield).
MS m/z: 262 (M+H).
Preparation 15
1-(3-bromo-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)ethanone
##STR00029##
[0084] Scheme 5, step A: To a 0.degree. C. solution of
3-bromo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine; hydrochloride (0.52
g, 2.2 mmol) in dichloromethane (6 mL) is dropwise added
N,N-diisopropylethylamine (1.5 mL, 8.6 mmol) and acetyl chloride
(0.2 mL, 3 mmol). The reaction mixture is stirred at room
temperature for 24 h. Added saturated aqueous sodium bicarbonate
solution (15 mL) and stirred 5 min and removed the organic layer.
The aqueous layer is extracted with dichloromethane (2.times.25
mL). The combined organic phase is dried over magnesium sulfate,
filtered, and concentrated under reduced pressure. The residue is
dissolved in dichloromethane, adsorbed onto celite, and purified
via flash chromatography (silica gel) eluting with hexanes:acetone
[50:50 to 0:100] to give
1-(3-bromo-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)ethanone (0.440 g,
1.8 mmol, 83% yield). ES/MS m/z: 241 and 243 (M and M+2).
Preparation 16
tert-butyl
(2S,4R)-4-[(6-acetyl-5,7-dihydropyrrolo[3,4-b]pyridin-3-yl)oxy]-
-2-methyl-pyrrolidine-1-carboxylate
##STR00030##
[0086] Scheme 5, step B: To a scintillation vial with tert-butyl
(2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (0.399 g, 1.98
mmol), 1-(3-bromo-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)ethanone
(0.300 g, 1.24 mmol), cesium carbonate (1.22 g, 3.74 mmol) and
methanesulfonato(2-di-t-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-tri-1-
-propylbiphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (0.28 g,
0.33 mmol) is added toluene (12 mL) and the mixture is capped and
is heated at 75.degree. C. for 72 hours. The reaction mixture is
cooled and filtered through celite using acetone to rinse. The
filtrate is concentrated under reduced pressure. The residue is
taken up in dichloromethane and purified via flash chromatography
(silica gel) eluting with hexane:acetone[1:1 to 0:1] to give
tert-butyl
(2S,4R)-4-[(6-acetyl-5,7-dihydropyrrolo[3,4-b]pyridin-3-yl)oxy]-2-methyl--
pyrrolidine-1-carboxylate (0.109 g, 0.301 mmol, 24% yield). ES/MS
m/z: 306 (M+H--C.sub.4H.sub.9).
Preparation 17
1-[3-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-
-6-yl]ethanone; hydrochloride
##STR00031##
[0088] Scheme 5, step C: To a solution of tert-butyl
(2S,4R)-4-[(6-acetyl-5,7-dihydropyrrolo[3,4-b]pyridin-3-yl)oxy]-2-methyl--
pyrrolidine-1-carboxylate (0.108 g, 0.299 mmol) in dichloromethane
(3 mL) is added hydrochloric acid in 1,4-dioxane (0.4 mL, 2 mmol, 4
M solution). The mixture is stirred at room temperature for 2.5 h.
The suspension is concentrated under reduced pressure and the
residue is placed under vacuum for 1 h to give
1-[3-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridi-
n-6-yl]ethanone; hydrochloride (0.089 g, 0.299 mmol, 100% yield).
MS m/z: 262 (M+H).
Preparation 18
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone
##STR00032##
[0090] Scheme 3, step A: Purge a flask containing
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole (30.6 g, 124 mmol) and
[1,3-bis(diphenylphosphino)propane]palladium (II) dichloride (2.32
g, 3.85 mmole) with nitrogen and add ethylene glycol (240 mL) and
trimethylamine (50 mL, 359 mmol) and 1-vinyloxybutane (80 mL, 618
mmol). Heat the reaction at 100.degree. C. for 18 h. Cool the
reaction to room temperature and add 2.5 M aqueous HCl (500 mL,
1.300 mol) and stir for 1 hour. And ethyl acetate (400 mL) and
remove the organic layer. Extract the aqueous layer with EtOAc
(2.times.225 mL). Dry the combined organic layer over magnesium
sulfate, filter, and concentrate. Suspend the crude product in
65:35 water:MeOH, filter the slurry, and dry the solid to afford
the title compound
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone (16.7 g, 79.8
mmol, 64% yield). ES/MS m/z: 210 (M+H).
Alternative Preparation of
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone
[0091] To a flask is added
5-bromo-6-fluoro-2-methyl-1,3-benzothiazole (72.0 g, 293 mmol),
1,3-bis(diphenylphosphino)propane (2.41 g, 5.85 mmol) and
palladium(II) acetate (0.657 g, 2.93 mmol) at room temperature
under N.sub.2. To the flask is added ethylene glycol (720 mL),
1-vinyloxybutane (189 mL, 1460 mmol) and triethylamine (124 mL, 878
mmol). N.sub.2 is bubbled through the reaction mixture for 30
minutes with stirring at room temperature, then the reaction
mixture is stirred overnight in a 115.degree. C. heating block with
a condenser fitted (internal temperature 98.degree. C.). The
reaction mixture is cooled to room temperature and is poured into a
mixture of aq. 2M HCl (576 mL) and ice (50 g) over 15 minutes with
ice-water bath cooling, maintaining an internal temperature below
20.degree. C. during the addition. The mixture is stirred at room
temperature for 5 minutes, then is stirred in a 41.degree. C.
heating block for 30 minutes (internal temperature 40.degree. C.).
The reaction mixture is diluted with EtOAc (500 mL) and the mixture
is stirred at room temperature for 10 minutes, then is filtered
through diatomaceous earth. The filtrate is transferred to a
separating funnel and the layers are separated. The aqueous layer
is extracted with EtOAc (500 mL), then the combined organics are
washed with sat. aq. NaCl solution (500 mL), dried over
Na.sub.2SO.sub.4 and concentrated. The resultant residue is
suspended in 35% MeOH/water (162 mL) and the mixture is vigorously
agitated in a 45.degree. C. water bath on a rotary evaporator for
30 minutes, then is cooled to room temperature and filtered. The
filtered solid is dried under vacuum at 40.degree. C. overnight to
give the title compound (57.48 g, 93% yield) as a brown solid.
ES/MS m/z: 210 (M+H)
Preparation 19
(1 S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanol
##STR00033##
[0093] Scheme 3, step B: To an autoclave is added
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone (16.7 g, 79.8
mmol) and (R)-Rucy-xylBinap (CAS #1384974-38-2) (0.465 g, 0.385
mmol) and a 1M solution of potassium tert-butoxide in tert-butanol
(3.5 mL, 3.5 mmol) and toluene (240 mL). The autoclave is cooled to
-10.degree. C. and charged to 450 psi with hydrogen with stirring
at 500 rpm for 4.5 hours. The reaction is warmed to room
temperature and stirred for 15 hours. The reaction mixture is
concentrated. The residue is purified via flash chromatography
(silica gel) eluting with a gradient of 0-40% EtOAc in hexanes to
give (1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanol (15.8
g, 74.8 mmol, 94% yield). ES/MS m/z: 212 (M+H).
[.alpha.].sub.D.sup.20=-38.6.degree. (c=0.2, MeOH).
Alternative Preparation of
(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanol
[0094] To a flask is added
1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethanone (50.1 g, 239
mmol), 2-propanol (311 mL), aq. pH 7 potassium phosphate buffer
solution (0.1 M, 752 mL), KRED-P3-C12 (5.51 g; Codexis
Ketoreductase (KRED), lyophyilized enzyme powder, carbonyl
reductase, CAS #77106-95-7), magnesium sulfate (0.173 g, 1.44 mmol)
and NADP (0.501 g) at room temperature. The mixture is stirred in a
37.degree. C. heating block (internal temperature 36.degree. C.)
open to air overnight, then to the mixture is added KRED-P3-C12
(2.51 g), magnesium sulfate (0.0865 g, 0.718 mmol) and NADP (0.251
g) and the reaction mixture is stirred in a 37.degree. C. heating
block (internal temperature 36.degree. C.) overnight open to air
under a stream of N.sub.2 gas. To the reaction mixture is added
2-propanol (146 mL), KRED-P3-C12 (2.51 g), magnesium sulfate
(0.0865 g, 0.718 mmol) and NADP (0.251 g) and the reaction mixture
is stirred in a 37.degree. C. heating block (internal temperature
36.degree. C.) overnight open to air under a stream of N.sub.2 gas.
To the reaction mixture is added 2-propanol (91.5 mL), KRED-P3-C12
(0.501 g), magnesium sulfate (0.0288 g, 0.239 mmol) and NADP
(0.0501 g) and the reaction mixture is stirred in a 37.degree. C.
heating block (internal temperature 36.degree. C.) overnight open
to air under a stream of N.sub.2 gas. The reaction mixture is
diluted with water (400 mL) and EtOAc (400 mL) and filtered through
diatomaceous earth, washing with water (100 mL) and EtOAc (100 mL).
The filtrate is transferred to a separating funnel and the layers
are separated. The aqueous layer is extracted with EtOAc (500 mL),
then the combined organics are washed with water (1 L), dried over
Na.sub.2SO.sub.4 and concentrated to give the title compound (48.7
g, 96% yield) as a brown solid. Optical rotation
[.alpha.].sub.D.sup.20=-35.degree. (c=0.2, MeOH).
[0095] ES/MS m/z: 212 (M+H).
Preparation 20
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole
##STR00034##
[0097] Scheme 3, step C: To a solution of
(S)-1-(6-fluoro-2-methylbenzo[d]thiazol-5-yl)ethan-1-ol (15.8 g,
74.8 mmol) in dioxane (400 mL) is added 1-formylpyrrolidine (3.7
mL, 38 mmol) and benzoyl chloride (22 mL, 187 mmol). The reaction
is stirred at room temperature for 36 h. The reaction is cooled to
0.degree. C. and ethyl acetate (250 mL) is added followed by
dropwise addition of N,N-dimethylethylenediamine (12 mL, 110 mmol).
The solution is warmed to room temperature and stirred for 10
minutes. To the solution is added saturated aqueous citric acid
solution (200 mL). The solution is diluted with ethyl acetate (250
mL) and water (250 mL). The aqueous layer is removed and extracted
with ethyl acetate (2.times.125 mL). The combine organic layers are
washed with saturated aqueous sodium carbonate (200 mL). This
aqueous wash is back extracted with ethyl acetate (100 mL). The
combined organic layers are washed with brine (100 mL) and then
dried over magnesium sulfate, filtered, and concentrated. The
residue is purified by via flash chromatography (silica gel)
eluting with hexanes:DCM (97:3 to 50:50) to give
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole (13.2 g,
57.6 mmol, 77% yield). ES/MS m/z: 230 (M+H).
Example 1
1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methylp-
yrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)ethan-1-on-
e
##STR00035##
[0099] Scheme 1, step D (X=N): To a solution of
6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde (0.920 g, 4.71
mmol) and
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,-
4-d]pyrimidin-6-yl)ethan-1-one hydrochloride (1.48 g, 4.95 mmol) in
DCM (46 mL) is added DIPEA (2.4 mL, 14 mmol). The resulting
solution is stirred at RT for 1 h. To the solution is added
NaBH(OAc).sub.3 (3.0 g, 14.2 mmol). The resulting solution is
stirred at RT for 16 h. The reaction mixture is quenched slowly
with saturated aqueous NaHCO.sub.3 (10 mL) and diluted with water
(50 mL). The aqueous layer is extracted with DCM (2.times.50 mL).
The combined organic extracts are dried over MgSO.sub.4, filtered,
and concentrated under reduced pressure. The resulting residue is
dissolved in DCM and purified via flash chromatography over silica
gel, eluting with a gradient of 10-100% acetone in hexanes followed
by isocratic 10% methanol in EtOAc to obtain the title compound
after solvent evaporation of the desired chromatographic fractions
(1.68 g, 81% yield). ES/MS m/z: 442 (M+H);
[.alpha.].sub.D.sup.20=+55.3.degree. (c=0.2, MeOH).
Alternative Procedure for Example 1
[0100] To a flask is added
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]-
pyrimidin-6-yl)ethan-1-one (18.2 g, 45.1 mmol) and DCM (178 mL).
The mixture is stirred in an ice-water bath (internal temperature
5.degree. C.) and to the mixture is added
6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde (8.9 g, 45.1
mmol), pyridine (7.3 mL, 90 mmol) and NaBH(OAc).sub.3 (19.1 g, 90.1
mmol). The reaction mixture is stirred at RT overnight (internal
temperature 20.degree. C.), cooled in an ice-water bath, and
aqueous 10% Na.sub.2CO.sub.3 solution (130 mL) is added over 5 min,
maintaining an internal temperature below 15.degree. C. during the
addition. The mixture is stirred vigorously at RT for 15 min, the
layers are separated, and the aqueous layer is extracted with DCM
(2.times.90 mL). The combined organic extracts are dried over
Na.sub.2SO.sub.4, filtered, and the filtrate is concentrated to
give a residue, which is purified by flash chromatography over
silica, using a gradient of 0-15% isopropanol/DCM. The
product-containing fractions are concentrated under reduced
pressure. The resulting residue is concentrated from heptane (100
mL) to obtain the title compound (15.64 g, 76% yield) as a
cream-colored solid. The solid is combined with two other lots of
similar purity and the combined material (19.86 g, 43.65 mmol) is
combined with EtOAc (149 mL) and heptane (149 mL) at RT. The
mixture is stirred vigorously in a 45.degree. C. heating block for
30 min, cooled to RT and stirred for 15 min, and is filtered. The
filtered solid is dried under vacuum at 40.degree. C. overnight to
give the title compound (18.81 g, 96% yield) as an off-white solid.
ES/MS m/z: 442 (M+H); [ ].sub.D.sup.20=+59.8.degree. (c=0.2,
MeOH).
Example 2
1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methylp-
yrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one
##STR00036##
[0102] Scheme 1, step D (X=CH): To a solution of
6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde (0.19 g, 0.95
mmol) and
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,-
4-b]pyridin-6-yl)ethan-1-one hydrochloride (0.28 g, 0.94 mmol) in
DCM (9 mL) is added DIPEA (0.45 mL, 2.6 mmol). The resulting
solution is stirred at RT for 40 min. To the solution is added
NaBH(OAc).sub.3 (0.65 g, 3.04 mmol). The resulting solution is
stirred at RT for 17 h. The reaction mixture is quenched slowly
with saturated aqueous NaHCO.sub.3 (5 mL). The aqueous layer is
extracted with DCM (2.times.5 mL). The combined organic extracts
are dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure. The resulting residue is dissolved in DCM and purified
via flash chromatography over silica gel, eluting with a gradient
of 40-100% acetone in hexanes, to obtain the title compound after
solvent evaporation of the desired chromatographic fractions (0.27
g, 65% yield). ES/MS m/z: 441 (M+H); [.alpha.].sub.D.sup.20=+101.40
(c=0.2, MeOH).
Alternative Preparation of
1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methyl-
pyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one
Preparation of 4-Methylbenzenesulfonic acid;
(3R,5S)-5-methylpyrrolidin-3-ol
##STR00037##
[0104] To a flask is added tert-butyl
(2S,4R)-4-hydroxy-2-methyl-pyrrolidine-1-carboxylate (53.0 g, 263
mmol) and 2-propanol (265 mL) at room temperature. The mixture is
stirred at room temperature (internal temperature 20.degree. C.)
and p-toluenesulfonic acid monohydrate (60.1 g, 316 mmol) is added
in one portion. The reaction mixture is stirred in a 62.degree. C.
heating block overnight, then is cooled to room temperature and
concentrated to approximately 150 mL total volume. The mixture is
diluted with MTBE (530 mL) and the mixture is stirred vigorously at
room temperature for 30 minutes and then is filtered under flow of
N.sub.2 gas. The filtered solid is dried under vacuum at 40.degree.
C. for 2 hours to provide 4-methylbenzenesulfonic acid;
(3R,5S)-5-methylpyrrolidin-3-ol (67.6 g, 93% yield) as a white
solid. ES/MS m/z: 102 (M+H).
Preparation of
(3R,5S)-1-[(6-Fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methyl-pyrr-
olidin-3-ol
##STR00038##
[0106] To a flask is added 4-methylbenzenesulfonic acid;
(3R,5S)-5-methylpyrrolidin-3-ol (61.9 g, 226 mmol), EtOAc (850 mL)
and 6-fluoro-2-methyl-1,3-benzothiazole-5-carbaldehyde (42.5 g, 216
mmol) at room temperature. The reaction mixture is stirred in an
ice-water bath (internal temperature 3.degree. C.) and
triethylamine (60.1 mL, 431 mmol) is added in one portion. The
reaction mixture is stirred in an ice-water bath for 30 minutes,
then sodium triacetoxyborohydride (91.4 g, 431 mmol) is added in
one portion. The reaction mixture is stirred in an ice-water bath
for 10 minutes, then at room temperature for 2 hours (internal
temperature 20.degree. C.). The reaction mixture is stirred in an
ice-water bath and 15% aq. KHSO.sub.4 solution (650 mL) is added
over 5 minutes, maintaining an internal temperature below
15.degree. C. during the addition. The mixture is stirred
vigorously at room temperature for 1 hour, then sat. aq. citric
acid solution (100 mL) is added and the mixture is stirred at room
temperature for 5 minutes, then the layers are separated. The
aqueous layer is washed with EtOAc (400 mL), then the aqueous layer
is stirred in an ice-water bath and solid Na.sub.2CO.sub.3 (80 g)
is added portionwise over 10 minutes with vigorous stirring until
pH=10 (measured by pH paper). The aqueous layer is then extracted
with EtOAc (3.times.400 mL). The combined organics are dried over
Na.sub.2SO.sub.4 and concentrated to give a residue that is crushed
into a fine powder using a pestle and mortar, then is combined with
25% MTBE/heptane (280 mL). The mixture is stirred vigorously in a
45.degree. C. heating block for 1 hour, then at room temperature
for 1 hour and then is filtered to give the first batch of filtered
solid. The filtrate is concentrated, then the residue is combined
with 25% MTBE/heptane (40 mL) and the mixture is stirred vigorously
at room temperature for 30 minutes and then is filtered to give the
second batch of filtered solid. The first and second batches of
filtered solids are combined and the mixture is ground up with a
spatula, then is dried under vacuum at room temperature overnight
to provide
(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methyl-pyrr-
olidin-3-ol (53.3 g, 87% yield) as a cream-coloured solid. ES/MS
m/z: 281 (M+H).
Preparation of final title compound
1-(2-(((3R,5S)-1-((6-fluoro-2-methylbenzo[d]thiazol-5-yl)methyl)-5-methyl-
pyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan-1-one
[0107] To a flask is added
(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methyl-pyrr-
olidin-3-ol (26.9 g, 95.0 mmol),
1-(2-chloro-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)ethanone (22.1 g,
109 mmol), cesium carbonate (92.8 g, 285 mmol), MorDalPhos (1.76 g,
3.80 mmol), palladium(II)(pi-cinnamyl) chloride dimer (984 mg, 1.90
mmol) and toluene (538 mL) at room temperature. N.sub.2 gas is
bubbled through the mixture at room temperature with stirring for
30 minutes, then the reaction mixture is stirred in a 86.degree. C.
heating block overnight (internal temperature 80.degree. C.). The
reaction mixture is cooled to room temperature and diluted with
EtOAc (269 mL) and diatomaceous earth (27 g) is added. The mixture
is stirred at room temperature for 5 minutes, then is filtered
through diatomaceous earth, washing with EtOAc (200 mL). The
filtrate is concentrated to give a residue, which is dissolved in
EtOAc (100 mL) and the mixture is passed through a short pad of
silica gel (300 g), eluting with EtOAc (2 L) and then with 20%
IPA/EtOAc (2 L). The IPA/EtOAc fraction is concentrated to give a
residue, which is dried under vacuum at room temperature for 1 hour
to give the title compound (42.1 g, 88% yield, 88% purity by mass)
as a pale brown foam.
[0108] The foam is combined with another lot of similar purity and
the combined material (46.0 g, 92.3 mmol) is combined with MTBE
(230 mL) and heptane (230 mL) at room temperature. The mixture is
stirred vigorously in a 45.degree. C. heating block for 1 hour,
then at room temperature for 30 minutes and then is filtered. The
filtered solid is combined with EtOAc (400 mL) and SiliaMetS Thiol
(40 g) is added. The mixture is agitated on a rotary evaporator at
room temperature for 1 hour, then is filtered. The filtrate is
concentrated to give a residue, which is combined with 25%
EtOAc/heptane (400 mL) and the mixture is stirred vigorously in a
50.degree. C. heating block for 1 hour, then at room temperature
for 10 minutes, then is filtered, keeping aside the first batch of
filtrate. The filtered solid is combined with 35% EtOAc/heptane
(400 mL) and the mixture is stirred vigorously in a 50.degree. C.
heating block for 1 hour, then at room temperature for 10 minutes,
then is filtered, keeping aside the second batch of filtrate. The
filtered solid is combined with EtOAc (500 mL) and 15% aq.
KHSO.sub.4 solution (500 mL). The mixture is stirred vigorously at
room temperature for 15 minutes, then is transferred to a
separating funnel and the layers are separated, leaving a rag layer
in the organics. The organic layer is further extracted with 15%
aq. KHSO.sub.4 solution (100 mL), leaving a rag layer in the
organics. The rag layer is removed from the organics and is diluted
with CH.sub.2C2 (100 mL) and 15% aq. KHSO.sub.4 solution (100 mL)
and the layers are separated. The combined aqueous layers are
stirred in an ice-water bath and solid Na.sub.2CO.sub.3 (100 g) is
added portionwise over 5 minutes with stirring (pH measured as 10
by pH paper). The mixture is extracted with CH.sub.2C2 (2.times.500
mL) and the combined organics are dried over Na.sub.2SO.sub.4 and
concentrated to give the first batch of crude product. The first
and second batches of filtrates from the filtrations are combined
and concentrated, then the residue is combined with EtOAc (100 mL)
and 15% aq. KHSO.sub.4 solution (100 mL). The mixture is stirred
vigorously at room temperature for 15 minutes, then is transferred
to a separating funnel and the layers are separated. The aqueous
layer is stirred in an ice-water bath and solid Na.sub.2CO.sub.3
(15 g) is added portionwise over 5 minutes with stirring (pH
measured as 10 by pH paper). The mixture is extracted with
CH.sub.2C2 (2.times.100 mL) and the combined organics are dried
over Na.sub.2SO.sub.4 and concentrated to give a residue which is
combined with 25% EtOAc/heptane (80 mL) and the mixture is stirred
vigorously in a 50.degree. C. heating block for 30 minutes, then at
room temperature for 10 minutes, then is filtered to give the
second batch of crude product. The two batches of crude product are
combined with 25% EtOAc/heptane (400 mL) and the mixture is stirred
vigorously in a 50.degree. C. heating block for 30 minutes, then at
room temperature for 10 minutes, then is filtered. The filtered
solid is dried under vacuum at room temperature 3 days to provide
the final title compound (37.4 g, 90% yield) as a white solid.
ES/MS m/z: 441 (M+H). Optical rotation
[.alpha.]D.sub.20=+104.0.degree. (c=0.2, MeOH).
Example 3
1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methyl-
-pyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]ethanone
##STR00039##
[0110] Scheme 4, step D: To a scintillation vial containing
6-fluoro-2-methyl-1.3-benzothiazole-5-carbaldehyde (0.071 g, 0.363
mmol) and
1-[6-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]py-
ridin-2-yl]ethanone; hydrochloride (0.1 g, 0.335 mmol) in
dichloromethane (3.5 mL) is added N,N-diisopropylethylamine (0.175
mL, 1 mmol). The solution is stirred at room temperature and sodium
triacetoxyborohydride (0.220 g, 1.038 mmol) is added. The solution
is stirred at room temperature for 20 hours. The reaction is slowly
quenched with saturated aqueous sodium bicarbonate (3 mL). The
aqueous layer is extracted with dichloromethane (3.times.5 mL). The
combined organic phase is dried over magnesium sulfate, filtered,
and concentrated under reduced pressure. The residue is purified by
reverse phase HPLC (solvent A: aqueous 10 mM ammonium bicarbonate
pH=10/5% MeOH, solvent B: acetonitrile, Phenomenex Kinetex EVO C18,
100.times.30 mm column, 50.degree. C. column heater) to give
1-[6-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5--
methyl-pyrrolidin-3-yl]oxy-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl]ethanone
(0.089 g, 0.203 mmol, 56% yield). ES/MS m/z: 441 (M+H).
[.alpha.].sub.D.sup.20=+22.5.degree. (c=0.2, MeOH).
Example 4
1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5-methyl-
-pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone
##STR00040##
[0112] Scheme 5, step D: To a solution of
6-fluoro-2-methyl-1.3-benzothiazole-5-carbaldehyde (0.057 g, 0.292
mmol) and
1-[3-[(3R,5S)-5-methylpyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]py-
ridin-6-yl]ethanone; hydrochloride (0.089 g, 0.299 mmol) in
dichlormethane (3 mL) is added N,N-diisopropylethylamine (0.15 mL,
0.86 mmol). The solution is stirred at room temperature and sodium
triacetoxyborohydride (0.188 g, 0.877 mmol) is added. The solution
is stirred at room temperature for 23 hours. The reaction is slowly
quenched with saturated aqueous sodium bicarbonate (5 mL). The
aqueous layer is extracted with dichloromethane (3.times.5 mL). The
combined organic phase is dried over magnesium sulfate, filtered,
and concentrated under reduced pressure. The residue is purified by
reverse phase HPLC (solvent A: aqueous 10 mM ammonium bicarbonate
pH=10/5% MeOH, solvent B: acetonitrile, Phenomenex Kinetex EVO C18,
100.times.30 mm column, 50.degree. C. column heater) to give
1-[3-[(3R,5S)-1-[(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)methyl]-5--
methyl-pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone
(0.055 g, 0.125 mmol, 43% yield). MS m/z: 441 (M+H).
[.alpha.].sub.D.sup.20=+50.7.degree. (c=0.2, MeOH).
Example 5
1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethyl]-5--
methyl-pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]ethanon-
e
##STR00041##
[0114] Scheme 3, step D: To a solution of
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]-
pyrimidin-6-yl)ethan-1-one hydrochloride (0.165 g, 0.552 mmol) in
acetonitrile (4.0 mL) is added
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole (0.097
g, 0.422 mmol) and cesium carbonate (1.4 g, 4.3 mmol). The
suspension is stirred at 68.degree. C. for 21 h. The crude reaction
is cooled to room temperature and filtered through celite. The
filtrate is concentrated and purified via reverse phase
chromatography on a Phenomenex Kinetex EVO C18 column with aqueous
0.1% formic acid:MeCN as the mobile phase. This material is further
purified on a Chiralcel OD-H column with 40% MeOH (0.2%
IPAm)/CO.sub.2 as the mobile phase to give
1-(2-(((3R,5S)-1-((S)-1-(6-fluoro-2-methylbenzo[d]thiazol-5-yl)ethyl)-5-m-
ethylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)etha-
n-1-one (0.050 g, 0.110 mmol, 26% yield). MS m/z: 456 (M+H).
[.alpha.].sub.D.sup.20=13.8.degree. (c=0.2, MeOH).
Example 6
1-[2-[(3R,5S)-1-[(1S)-1-(6-fluoro-2-methyl-1,3-benzothiazol-5-yl)ethyl]-5--
methyl-pyrrolidin-3-yl]oxy-5,7-dihydropyrrolo[3,4-b]pyridin-6-yl]ethanone
##STR00042##
[0116] Scheme 3, step D: To a solution of
1-(2-(((3R,5S)-5-methylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]-
pyridin-6-yl)ethan-1-one hydrochloride (0.192 g, 0.644 mmol) in
acetonitrile (5.0 mL) is added
5-[(1R)-1-chloroethyl]-6-fluoro-2-methyl-1,3-benzothiazole (0.104
g, 0.452 mmol) and cesium carbonate (1.56 g, 4.79 mmol). The
suspension is stirred at 65.degree. C. for 17 h. The crude reaction
is cooled to room temperature and filtered through celite. The
filtrate is concentrated and purified via flash chromatography
(silica gel) eluting with hexanes:(3:1 acetone:DCM) [60:40 to
0:100]. This material is further purified on a Chiralpak AD-H
column with 40% MeOH (0.2% IPAm)/CO.sub.2 as the mobile phase to
give
1-(2-(((3R,5S)-1-((S)-1-(6-fluoro-2-methylbenzo[d]thiazol-5-yl)ethyl)-5-m-
ethylpyrrolidin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)ethan--
1-one (0.033 g, 0.073 mmol, 16% yield). MS m/z: 455 (M+H).
[.alpha.].sub.D.sup.20=+19.5.degree. (c=0.2, MeOH).
In Vitro Human OGA Enzyme Assay
Generation of OGA Enzyme
[0117] The nucleotide sequence encoding full-length human
O-GlcNAc-.beta.-N-acetylglucosaminidase (NM_012215) is inserted
into pFastBacl (Invitrogen) vector with an N-terminal
poly-histidine (HIS) tag. Baculovirus generation is carried out
according to the Bac-to-Bac Baculovirus Expression system
(Invitrogen) protocol. Sf9 cells are infected at 1.5.times.10.sup.6
cells/mL using 10 mL of P1 virus per Liter of culture and incubated
at 28.degree. C. for 48 hrs. Cells are spun down, rinsed with PBS
and the pellets stored at -80.degree. C.
[0118] The above OGA protein (His-OGA) is purified as follows: 4 L
of cells are lysed in 200 mL of buffer containing 50 mM Tris, pH
8.0, 300 mM NaCl, 10% glycerol, 10 mM imidazole, 1 mM
dithiothreitol (DTT), 0.1% Triton.TM. X-100, 4 tablets of protease
inhibitors (complete EDTA-Free, Roche) for 45 min at 4.degree. C.
This cell lysate is then spun for 40 min at 16500 rpm at 4.degree.
C., and supernatant incubated with 6 mL of Ni-NTA resin
(nickel-nitrilotriacetic acid) for 2 h at 4.degree. C.
[0119] Resin is then packed onto column and washed with 50 mM Tris,
pH 8.0, 300 mM NaCl, 10% glycerol, 10 mM imidazole, 0.1% Triton.TM.
X-100, 1 mM DTT, followed by 50 mM Tris, pH 8.0, 150 mM NaCl, 10 mM
imidazole, 10% glycerol, 1 mM DTT. The proteins are eluted with 50
mM Tris, pH 8.0, 150 mM NaCl, 300 mM imidazole, 10% glycerol, 1 mM
DTT. Pooled His-OGA containing fractions are concentrated to 6 ml
and loaded onto Superdex75 (16/60). The protein is eluted with 50
mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM DTT. Fractions
containing His-OGA are pooled and protein concentration measured
with BCA (Bradford Colorimetric Assay).
OGA Enzyme Assay
[0120] The OGA enzyme catalyses the removal of O-GlcNAc from
nucleocytoplasmic proteins. To measure this activity Fluorescein
di-N-acetyl-.beta.-N-acetyl-D-glucosaminide (FD-GlcNAc, Kim, Eun
Ju; Kang, Dae Ook; Love, Dona C.; Hanover, John A. Carbohydrate
Research (2006), 341(8), 971-982) is used as a substrate at a final
concentration of 6.7 .mu.M. This fluorogenic substrate becomes
fluorescent upon cleavage by OGA, so that the enzyme activity can
be measured by the increase in fluorescence detected at 535 nm
(excitation at 485 nm).
[0121] The assay buffer is prepared to give a final concentration
of 50 mM H.sub.2NaPO.sub.3--HNa.sub.2PO.sub.3, 0.01% bovine serum
albumin and 0.01% Triton.TM. X-100 in water, at pH 7. Compounds to
be tested are diluted in pure dimethyl sulfoxide (DMSO) using ten
point concentration response curves. Maximal compound concentration
in the reaction mixture is 30 or 1 .mu.M. Compounds at the
appropriate concentration are pre-incubated with OGA enzyme for 30
minutes before the reaction is started by the addition of
substrate. The final enzyme concentration is 3.24 nM or 0.5 nM, for
the 30 or 1 .mu.M maximal compound concentration, respectively.
Reactions are allowed to proceed for 60 min at room temperature.
Then, without stopping the reaction, fluorescence is read.
IC.sub.50 values are calculated by plotting the normalized data vs.
log of the compound and fitting the data using a four parameter
logistic equation.
[0122] The compounds of Examples 1 through 6 were tested
essentially as described above.
TABLE-US-00001 TABLE 1 Example IC.sub.50 (nM) 1 0.465 .+-. 0.224 (n
= 5) 2 0.214 .+-. 0.037 (n = 4) 3 0.782 .+-. 0.087 (n = 3) 4 0.592
.+-. 0.068 (n = 2) 5 0.495 .+-. 0.109 (n = 3) 6 0.385 .+-. 0.088 (n
= 3)
[0123] The results in Table 1 demonstrate that the compounds of
Examples 1 through 6 inhibit OGA enzyme activity in vitro.
* * * * *